Gene therapy preparations manufacturing · Pennsylvania

Spark Therapeutics, Inc

Philadelphia, PA · ~150 workers · 5 years of OSHA Injury Tracking Application data.

A
Excellent Safety Record
0.5
Avg TCR
3.3
Industry avg
0
Fatalities
Subscribe to safety-record updates (RSS)

The verdict

Spark Therapeutics, Inc runs at 16% of its industry's injury rate - far safer than the typical Gene therapy preparations manufacturing workplace, earning a grade A.

Spark Therapeutics, Inc: 0.5 TCR = 16% of Gene therapy preparations manufacturing BLS 3.3 · 5y Form 300A (see methodology below)

Spark Therapeutics, Inc safety composite

Spark Therapeutics, Inc scores strongest on dart rate (safer than 83% of same-industry peers) and weakest on fatalities (safer than 50%), blended into one 0-100 breakdown against same-industry peers. A missing measure drops out and redistributes its weight rather than deflating the score. This is a per-dimension breakdown, distinct from the single letter grade above it (which weights TCR alone against the BLS industry benchmark).

C

72/100

Percentile-weighted across 3 of 3 measures

Total Case Rate (TCR)
B 0.54 per 100 workers

Safer than 76% of industry peers

DART rate
B 0 per 100 workers

Safer than 83% of industry peers

Fatalities
D 0

Safer than 50% of industry peers

Benchmarked live against every credibly-rated employer in the same NAICS industry code in the current OSHA extract (a segment must have at least 8 rated peers to benchmark). Not a legal or compliance determination; PlainSafetyScore's own weighting (TCR 40%, DART 35%, fatalities 25%).

TCR Δ

−0.8

2020→2024

Spark Therapeutics, Inc injury rate improved

Spark Therapeutics, Inc's TCR fell 0.8 from 0.8 in 2020 to 0.0 in 2024. Peak filing year was 2023 at 1.9 TCR. In 2024, DART was 0× this establishment's average TCR (severity share of cases).

2020=0.8 · 2021=0.0 · 2022=0.0 · 2023=1.9 · 2024=0.0

OSHA ITA Form 300A scorecard

Establishment book 325414 · Philadelphia, PA AT/BELOW-IND · MID

Grade A · TCR 0.5 · 16% of ind

  • DART 0.0 DART
  • RANK #3/13
  • PHOTO Merck Teknika Facility
  • BOOK 5y book
  • INJ 3 inj
  • SIZE ~150 FTE

Nearest TCR peer: Merck Teknika Facility (0.0 TCR gap)

Read with this employer → · Industry book → · Pennsylvania employers → · Look up another →

Spark Therapeutics, Inc in the TCR neighbourhood

Average Total Case Rate among this establishment and nearest same-industry peers

TCR

What this shows Spark Therapeutics, Inc averages 0.5 TCR (16% of the Gene therapy preparations manufacturing BLS benchmark).

Source U.S. Department of Labor, OSHA Injury Tracking Application (Form 300A) As of 2026-08-25

Spark Therapeutics, Inc TCR series: 2020=0.8 · 2021=0 · 2022=0 · 2023=1.9 · 2024=0 · BLS 3.3

Where Spark Therapeutics, Inc falls in its industry

234 Gene therapy preparations manu establishments

Safer than 76% of graded establishments in this industry, whose median TCR is 1.2.

More dangerous than peersSafer than peers

Narrower to Pennsylvania alone (the establishments it most directly competes with for workers and contracts): ranked #3 safest of 13 Gene therapy preparations manu employers in Pennsylvania.

Spark Therapeutics, Inc (150 employees, TCR 0.5) among 29 same-industry peers, split at the industry median of 198 employees and a TCR of 1.2 2×2 strategic matrix plotting 30 entities by Average employees (X) and Total Case Rate (Y), with a crosshair dividing the plot into four quadrants. Larger & higher-riskSmaller & higher-riskLarger & saferSmaller & safer than peers 05001,0001,5002,000 0246 Average employees Total Case Rate Spark Therapeutics, Inc
Spark Therapeutics, Inc (150 employees, TCR 0.5) among 29 same-industry peers, split at the industry median of 198 employees and a TCR of 1.2

Spark Therapeutics, Inc has fewer employees than the Gene therapy preparations manufacturing median and a lower injury rate than the industry's median TCR of 1.2. Workforce size and injury rate do not always move together within the same industry -- some of its smaller peers run higher rates than its larger ones, and vice versa.

Year-by-Year Safety Data

Year TCR DART Injuries Illnesses Fatalities
2024 0.0 0.0 0 0 0
2023 1.9 1.0 2 0 0
2022 0.0 0.0 0 0 0
2021 0.0 0.0 0 0 0
2020 0.8 0.8 1 0 0

OSHA ITA peer cross-reference

Establishment peer ledger

325414 · PA · Philadelphia

234 Gene therapy preparations manufacturing employers nationwide with a credible TCR · 22,692 rated employers in Pennsylvania with headcount on file · 1,431 employers in Philadelphia, PA · 4 cross-state NAT-TCR peers · 4 cross-state NAT-SIZE peers. Closest matches by relationship code are listed below.

Rel Establishment Metric
NAICS-TCR Merck Teknika Facility 0.5 TCR
NAICS-TCR Zoetis LLC. 0.5 TCR
NAICS-TCR Bristol Myers Squibb - Summit West Cell Therapy Manufacturing 0.6 TCR
NAICS-TCR CELLECTIS BIOLOGICS INC. 0.5 TCR
STATE-SIZE UGI Middletown 150 FTE
STATE-SIZE Hagen Construction 150 FTE
STATE-SIZE Bisco Refractories 150 FTE
STATE-SIZE CM3 Building Solutions 150 FTE
CITY-NEAR FIVE BELOW INC 19,600 FTE
CITY-NEAR Hospital of University of Pennsylvania 13,423 FTE
CITY-NEAR Children's Hospital of Philadelphia - Main Hospital 9,638 FTE
CITY-NEAR The Children's Hospital of Philadelphia - Main Campus 9,129 FTE
NAT-TCR Mt. Vernon 0.5 TCR
NAT-TCR Pruitt Tool & Supply Company 0.5 TCR
NAT-TCR Thunder Bay Community Health Service, Inc Hilman 0.5 TCR
NAT-TCR Aclara Technologies, LLC - Solon 0.5 TCR
NAT-SIZE Mennonite Friendship Communities 150 FTE
NAT-SIZE Michels Pacific Energy, Inc- CA- Santa Clara 150 FTE
NAT-SIZE Johnson, Finch & McClure Construction, Inc. 150 FTE
NAT-SIZE FLL-GH 150 FTE

Rel codes: NAICS-TCR · STATE-SIZE · CITY-NEAR · NAT-TCR/NAT-SIZE cross-state. Read with this employer →

Data Source: OSHA Injury Tracking Application (ITA), mandatory establishment-level injury/illness reports. Grades compare employer Total Case Rate (TCR) to BLS IIF industry benchmarks. Data covers years reported by this establishment: 2024, 2023, 2022, 2021, 2020. This is publicly available government data - not a legal determination of workplace conditions.
Data sourced from official public datasets. See our methodology for details.